Free Trial

OpGen (OPGN) Competitors

OpGen logo
$4.89 0.00 (0.00%)
As of 05/20/2025 12:55 PM Eastern

OPGN vs. DCGO, EUDA, XGN, CORBF, ATPC, SERA, KDLY, QIPT, PIII, and BDSX

Should you be buying OpGen stock or one of its competitors? The main competitors of OpGen include DocGo (DCGO), EUDA Health (EUDA), Exagen (XGN), Global Cord Blood (CORBF), Agape ATP (ATPC), Sera Prognostics (SERA), Kindly MD (KDLY), Quipt Home Medical (QIPT), P3 Health Partners (PIII), and Biodesix (BDSX). These companies are all part of the "healthcare" industry.

OpGen vs.

DocGo (NASDAQ:DCGO) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership.

OpGen received 252 more outperform votes than DocGo when rated by MarketBeat users. However, 73.13% of users gave DocGo an outperform vote while only 51.81% of users gave OpGen an outperform vote.

CompanyUnderperformOutperform
DocGoOutperform Votes
49
73.13%
Underperform Votes
18
26.87%
OpGenOutperform Votes
301
51.81%
Underperform Votes
280
48.19%

DocGo has higher revenue and earnings than OpGen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DocGo$520.50M0.27$6.86M-$0.02-69.50
OpGen$2.67M18.42-$32.67MN/AN/A

DocGo has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, OpGen has a beta of -1.71, meaning that its stock price is 271% less volatile than the S&P 500.

DocGo presently has a consensus price target of $3.56, indicating a potential upside of 156.12%. Given DocGo's stronger consensus rating and higher possible upside, analysts plainly believe DocGo is more favorable than OpGen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DocGo
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
OpGen
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

DocGo has a net margin of 4.35% compared to OpGen's net margin of -1,140.36%. DocGo's return on equity of 8.90% beat OpGen's return on equity.

Company Net Margins Return on Equity Return on Assets
DocGo4.35% 8.90% 5.72%
OpGen -1,140.36%N/A -287.58%

In the previous week, DocGo had 15 more articles in the media than OpGen. MarketBeat recorded 16 mentions for DocGo and 1 mentions for OpGen. DocGo's average media sentiment score of 0.75 beat OpGen's score of -0.36 indicating that DocGo is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DocGo
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
OpGen
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

56.4% of DocGo shares are owned by institutional investors. Comparatively, 2.7% of OpGen shares are owned by institutional investors. 2.7% of DocGo shares are owned by company insiders. Comparatively, 43.8% of OpGen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

DocGo beats OpGen on 13 of the 16 factors compared between the two stocks.

Get OpGen News Delivered to You Automatically

Sign up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OPGN vs. The Competition

MetricOpGenMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$49.23M$3.00B$5.43B$8.48B
Dividend YieldN/A31.24%5.22%4.11%
P/E RatioN/A13.2326.7920.05
Price / Sales18.42164.59394.72116.44
Price / CashN/A57.5638.2534.62
Price / Book-0.424.316.864.61
Net Income-$32.67M-$22.21M$3.22B$248.19M
7 Day Performance4.04%3.62%6.83%2.97%
1 Month Performance17.83%7.44%13.73%16.58%
1 Year Performance41.33%4.26%18.22%8.16%

OpGen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OPGN
OpGen
N/A$4.89
flat
N/A+26.7%$49.23M$2.67M0.00100Analyst Forecast
DCGO
DocGo
3.7383 of 5 stars
$1.45
-1.4%
$3.56
+145.5%
-54.3%$147.88M$520.50M5.182,920
EUDA
EUDA Health
N/A$3.88
+1.6%
N/A+67.2%$144.15M$4.01M0.002
XGN
Exagen
4.6444 of 5 stars
$6.33
+5.3%
$7.50
+18.5%
+218.7%$134.83M$56.72M-6.73220Analyst Revision
High Trading Volume
CORBF
Global Cord Blood
N/A$1.05
-3.7%
N/A-56.0%$127.63M$196.12M0.001,200
ATPC
Agape ATP
0.4327 of 5 stars
$2.03
-1.0%
N/A-57.0%$101.51M$1.32M-2.7840Earnings Report
SERA
Sera Prognostics
1.1819 of 5 stars
$2.32
+0.4%
N/A-74.8%$87.38M$115,000.00-2.34120Positive News
Earnings Report
KDLY
Kindly MD
1.111 of 5 stars
$13.96
+7.8%
N/AN/A$77.99M$2.47M-18.13N/A
QIPT
Quipt Home Medical
1.5582 of 5 stars
$1.40
-1.1%
$2.85
+104.3%
-33.7%$60.11M$244.72M-8.21800Gap Up
PIII
P3 Health Partners
2.2504 of 5 stars
$7.94
-0.6%
$16.25
+104.7%
-70.6%$57.03M$1.50B-9.45500Earnings Report
BDSX
Biodesix
2.593 of 5 stars
$0.30
-0.1%
$2.00
+564.5%
-82.8%$44.12M$71.32M-0.77220Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:OPGN) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners